Hematology TimesJCAR017 gets PRIME access, breakthrough designationDecember 21, 2016Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesCombo improves ORR, PFS in relapsed/refractory CLLDecember 19, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesCHMP recommends authorization of rituximab biosimilarDecember 18, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesCHMP recommends approval of topical gel for MFDecember 17, 2016Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesCAR met primary endpoint at interim analysis in DLBCLDecember 16, 2016Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesCharacterizing FL transformation, progressionDecember 15, 2016Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesEC authorizes new use for ofatumumab in CLLDecember 14, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesEC grants venetoclax conditional approval for CLLDecember 9, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesDrug produces responses in ‘challenging’ patientsDecember 9, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesGroup estimates global cancer cases, deaths in 2015December 8, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaRelated IssuesAMLALLHodgkin Lymphoma
Hematology TimesData suggest one BTK inhibitor could replace anotherDecember 8, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesObinutuzumab bests rituximab in FL studyDecember 6, 2016Lymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Hematology TimesNICE recommends taking ibrutinib off CDFNovember 30, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
Hematology TimesTazemetostat receives fast track designation for DLBCLNovember 29, 2016Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaFollicular Lymphoma
Hematology TimesNovel CLL drugs could greatly increase costsNovember 22, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
